DEVONIAN HEALTH GROUP INC.
  • HOME
  • OUR COMPANY
    • Corporate Overview
    • Management Team
    • Directors
  • TECHNOLOGY
  • PRODUCTS
    • Therapeutics
    • Cosmeceuticals
  • PIPELINE
    • Therapeutics Pipeline
    • Cosmeceuticals Pipeline
  • INVESTORS CENTER
    • Press Releases
    • Presentation to investors
    • Financial Reports
    • Investors and Stock Information
    • Corporate Governance
  • CAREERS
  • CONTACT
  • FR
Select Page

Press Releases

  • Press Releases
  • Presentation to investors
  • Financial Reports
  • Investors and Stock Information
  • Media
  • Corporate Governance
  • What’s New?

Devonian Health Group Announces the Closing of $1,805,000 Non-Brokered Financing

May 4, 2020

PRESS RELEASE For immediate release Devonian Health Group Announces the Closing of $1,805,000 Non-Brokered Financing.   QUÉBEC CITY, May 4, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical...

Devonian Health Group Announces an Increase to its Non-Brokered Financing to $2,000,000

Apr 24, 2020

PRESS RELEASE For immediate release Devonian Health Group Announces an Increase to its Non-Brokered Financing to $2,000,000.   QUÉBEC CITY, April 24, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical...

Devonian Health Group Announces the Issuance of Securities in Interest Settlement Due to Debenture Holders, a $330,000 Non-Brokered Financing and the Grant of Options

Apr 22, 2020

PRESS RELEASE For immediate release Devonian Health Group Announces the Issuance of Securities in Interest Settlement Due to Debenture Holders, a $330,000 Non-Brokered Financing and the Grant of Options.   QUÉBEC CITY, April 22, 2020 – Devonian Health Group Inc....

Devonian Health Group Announces R-Spinasome® anti-aging technology global sales and marketing partnership

Feb 11, 2020

PRESS RELEASE For immediate release Devonian Health Group Announces R-Spinasome® anti-aging technology global sales and marketing partnership.   QUEBEC, February 11, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage...

Devonian issues settlements of interest due to a debenture holder and announces the results of the annual general meeting of shareholders

Jan 29, 2020

PRESS RELEASE For immediate release DEVONIAN ISSUES SETTLEMENTS OF INTEREST DUE TO A DEBENTURE HOLDER AND ANNOUNCES THE RESULTS OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS.   QUEBEC,  – January 29, 2020  Devonian Health Group Inc. (“Devonian” or the...

Devonian Health Group Announces presentation to the World Conference on Ageing and Gerontology and a correction on expiry date of warrants

Jan 23, 2020

PRESS RELEASE For immediate release Devonian Health Group Announces presentation to the World Conference on Ageing and Gerontology and a correction on expiry date of warrants.   QUEBEC, January 23, 2020 – Devonian Health Group Inc. (“Devonian” or the...

Devonian Health Group Announces Cannabis Cutting-Edge Extraction Equipment in its Montmagny Facility

Jan 16, 2020

PRESS RELEASE For immediate release Devonian Health Group Announces Cannabis Cutting-Edge Extraction Equipment in its Montmagny Facility.   QUEBEC, January 15, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage...

Devonian Health Group Obtains Cannabis Research License from Health Canada

Oct 3, 2019

PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP OBTAINS CANNABIS RESEARCH LICENSE FROM HEALTH CANADA.   QUEBEC, October 3, 2019 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical...

Devonian Health Group Announces the Formation of a Clinical Dermatology Advisory Board with mandate to assist in the development of Cannabinoids-based pharmaceutical products

Sep 4, 2019

PRESS RELEASE For immediate release Devonian Health Group Announces the Formation of a Clinical Dermatology Advisory Board with mandate to assist in the development of Cannabinoids-based pharmaceutical products.   QUEBEC, September 4, 2019 – Devonian Health Group...

Devonian Health Group announces the publication of positive results of the Purgenesis® Anti-aging Care clinical study in the Journal of Cosmetic Dermatology

Aug 29, 2019

PRESS RELEASE For immediate release Devonian Health Group announces the publication of positive results of the Purgenesis® Anti-aging Care clinical study in the Journal of Cosmetic Dermatology.   QUEBEC, August 28, 2019 – Devonian Health Group Inc. (“Devonian” or...

« Older Entries
Next Entries »
  • Press Releases
    • 2025
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Financial Reports
  • Investors and Stock Information
  • Media
  • Corporate Governance
  • What’s New
Location

360 rue des Entrepreneurs Montagny, Québec, Canada G5V4T1

Information de contact

Phone : +1 450-979-2916
E-mail : info@groupedevonian.com

Also visit our division's site
Altius Healthcare

OUR COMPANY

  • Corporate Overview
  • Management Team
  • Directors

INVESTOR CENTER

  • Press Releases
  • Financial Reports
  • Investors and Stock Information
  • Corporate Governance

Subscribe to get corporate news and press releases

"*" indicates required fields

  • PRIVACY POLICY
  • TERMS OF USE
© 2022 - Tous droits réservés - Groupe Santé Devonian inc.
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}